Opportunity Information: Apply for PAR 13 310
Apply for PAR 13 310
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Aug 5, 2013 and posted on Aug 5, 2013.
- Applicants must submit their applications by Aug 16, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education County governments Small businesses For profit organizations other than small businesses Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Special district governments State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03)" (Funding Opportunity Number PAR-13-310) supported small, focused projects aimed at improving how drugs are used and developed for two populations that often lack strong evidence from traditional drug studies: children across different developmental stages and pregnant women (including impacts on the developing fetus). The central idea was to move beyond basic observations and generate translational and clinical evidence, including clinical trials when appropriate, that clarifies how and why drugs work the way they do in these groups, how responses differ by age or pregnancy status, and what factors drive safety concerns. In practical terms, the FOA emphasized research that could lead to safer prescribing, more effective dosing, better risk prediction, and more tailored therapies for pediatric and obstetric patients.
The scientific scope focused on advancing knowledge of mechanisms of drug action, variability in response, and safety. For pediatric populations, this includes the reality that newborns, infants, children, and adolescents can differ substantially in drug absorption, distribution, metabolism, and elimination, as well as in receptor sensitivity and organ maturity, meaning adult data often do not translate cleanly. For obstetric populations, pregnancy-related physiologic changes can alter drug exposure and effect, and fetal development introduces additional safety considerations. The FOA was designed to encourage studies that help explain these differences and turn that understanding into better clinical decision-making, whether through improved dosing strategies, identification of biomarkers of response or toxicity, characterization of developmental pharmacology, or evidence that supports safer use of existing therapies.
This opportunity used the NIH R03 mechanism, which typically supports short-term, limited-scope research projects. The listed award ceiling was $50,000, reflecting the expectation that applications would be targeted and feasible within a modest budget. Cost sharing or matching was not required, which is consistent with standard NIH practice and lowers barriers for applicants who may not have access to non-federal matching funds. The funding instrument type was a grant, and the activity category fell under health-related research, specifically under CFDA 93.865 (Child Health and Human Development Extramural Research), aligning it closely with NICHD-related priorities even though the agency name is listed broadly as the National Institutes of Health.
Eligibility was broad and included many types of U.S. organizations and governments as well as non-U.S. entities. Eligible applicants included state, county, city/township, special district, and tribal governments; public housing authorities/Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; nonprofits with and without 501(c)(3) status; small businesses; and for-profit organizations (including those other than small businesses). The FOA also explicitly included a range of institution types often highlighted in federal eligibility language, such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions. Importantly, the announcement allowed foreign organizations and foreign institutions to apply, allowed non-U.S. components of U.S. organizations to participate, and permitted foreign components as defined by NIH policy, signaling that international collaboration or non-U.S.-based research elements could be appropriate when justified.
From an administrative standpoint, this FOA was posted and created on August 5, 2013, with an original and current closing date of August 16, 2016, and it was archived on September 16, 2016, meaning it is no longer open for applications. The official information link was provided through the NIH Grants Guide (http://grants.nih.gov/grants/guide/pa-files/PAR-13-310.html). For access issues or linking problems, the contact was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV, which is a technical contact rather than a scientific/program contact.
Overall, PAR-13-310 was aimed at generating actionable, patient-centered evidence to close persistent gaps in pediatric and obstetric pharmacology. By encouraging translational and clinical studies, including clinical trials, it sought to improve real-world safety and effectiveness of existing drugs while also supporting steps toward new therapies or safer, more individualized use of current treatments for children and pregnant patients, where ethical, physiologic, and developmental complexities frequently limit the strength of available data.
FAQs: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03) (PAR-13-310)
What is PAR-13-310?
PAR-13-310 is an NIH funding opportunity titled "Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03)." It supported small, focused research projects intended to improve how drugs are used and developed for pediatric patients (across developmental stages) and for pregnant women, including consideration of impacts on the developing fetus.
What is the main purpose of this funding opportunity?
The purpose was to generate translational and clinical evidence (including clinical trials when appropriate) that helps explain how and why drugs work in children and in pregnancy, how responses differ by age or pregnancy status, and what factors contribute to safety risks. The overall aim was to enable safer prescribing, more effective dosing, better risk prediction, and more tailored therapies for pediatric and obstetric patients.
What does "translational research" mean in the context of this FOA?
In this FOA, translational research means moving beyond basic observations to produce evidence that can inform real clinical decision-making. This includes clarifying mechanisms of drug action, understanding variability in response, identifying safety drivers, and generating findings that can be used to improve dosing strategies, risk prediction, and patient-specific treatment choices.
Which patient populations were the focus?
The FOA focused on two populations that often lack strong evidence from traditional drug studies: (1) children across multiple developmental stages (newborns, infants, children, adolescents) and (2) pregnant women, including potential effects on the developing fetus.
Why does the FOA emphasize pediatrics?
The FOA emphasized pediatrics because drug absorption, distribution, metabolism, and elimination can vary substantially across developmental stages. Differences in receptor sensitivity and organ maturity also mean adult drug data often do not translate directly to newborns, infants, children, or adolescents.
Why does the FOA emphasize obstetric pharmacology?
Pregnancy can involve physiologic changes that alter drug exposure and drug effects. Additionally, fetal development adds safety considerations. The FOA encouraged studies that explain these pregnancy-related differences and translate that understanding into better clinical decision-making.
What kinds of research topics were encouraged?
The FOA encouraged research that advances knowledge of mechanisms of drug action, variability in response, and safety in pediatric and obstetric populations. Examples described in the opportunity include work that supports improved dosing strategies, identification of biomarkers of response or toxicity, characterization of developmental pharmacology, and evidence that supports safer use of existing therapies.
Were clinical trials allowed under this opportunity?
Yes. The FOA explicitly included translational and clinical evidence generation, including clinical trials when appropriate.
What NIH grant mechanism was used?
This opportunity used the NIH R03 mechanism, which typically supports short-term, limited-scope research projects.
What was the budget/award ceiling for this opportunity?
The listed award ceiling was $50,000, reflecting the expectation that proposed projects would be targeted, feasible, and limited in scope.
Was cost sharing or matching required?
No. The FOA stated that cost sharing or matching was not required.
What was the funding instrument type?
The funding instrument type was a grant.
What was the activity area/category?
The activity category was health-related research.
Which CFDA program was associated with this opportunity?
The FOA was associated with CFDA 93.865, described as Child Health and Human Development Extramural Research, aligning it closely with NICHD-related priorities (even though the agency is listed broadly as the National Institutes of Health).
Who was eligible to apply?
Eligibility was broad. The FOA listed many types of U.S. organizations and governments as eligible applicants, including: state, county, city/township, special district, and tribal governments; public housing authorities/Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; nonprofits with and without 501(c)(3) status; small businesses; and for-profit organizations (including those other than small businesses).
Were specific institution types explicitly included?
Yes. The FOA explicitly included institution types commonly highlighted in federal eligibility language, including Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions.
Could non-U.S. (foreign) organizations apply?
Yes. The FOA allowed foreign organizations and foreign institutions to apply.
Could a U.S. organization include non-U.S. components in the project?
Yes. The FOA allowed non-U.S. components of U.S. organizations to participate, and it permitted foreign components as defined by NIH policy.
Is this funding opportunity still open?
No. The FOA is no longer open for applications. It had an original and current closing date of August 16, 2016, and it was archived on September 16, 2016.
When was the opportunity posted?
The FOA was posted/created on August 5, 2013.
Where is the official FOA posted?
The official information link was provided through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-310.html.
Who should be contacted for technical issues with the FOA link or access?
For access issues or linking problems, the FOA listed the NIH Office of Extramural Research (OER) webmaster as the contact: FBOWebmaster@OD.NIH.GOV. This is described as a technical contact rather than a scientific or program contact.
What kinds of real-world outcomes was this FOA trying to support?
The FOA aimed to close evidence gaps that often limit confident prescribing in children and pregnant patients. It emphasized generating actionable, patient-centered evidence that could support safer prescribing, more effective dosing, improved prediction of adverse risks, and more individualized therapy choices in pediatric and obstetric care.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21)
Previous opportunity: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 310
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 310) also looked into and applied for these:
| Funding Opportunity |
|---|
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21) Apply for PAR 13 311 Funding Number: PAR 13 311 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01) Apply for PAR 13 325 Funding Number: PAR 13 325 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21) Apply for PAR 13 326 Funding Number: PAR 13 326 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R03) Apply for PAR 13 344 Funding Number: PAR 13 344 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R43) Apply for PAR 13 345 Funding Number: PAR 13 345 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems STTR (R41) Apply for PAR 13 346 Funding Number: PAR 13 346 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Sustained Release of Antivirals for Treatment and Prevention of HIV (SRATP) (R01) Apply for PAR 13 349 Funding Number: PAR 13 349 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Enhancing the Capacity for Biomedical Research on Tuberculosis for HIV infected Mothers and Children in India (R01) Apply for RFA HD 14 025 Funding Number: RFA HD 14 025 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $350,000 |
| Developmental Origins of Health and Disease (DOHaD) Epigenetic Modification in Gametogenesis and Transgenerational Inheritance (R01) Apply for PAR 13 385 Funding Number: PAR 13 385 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Female Contraceptive Development Program (U01) Apply for RFA HD 14 024 Funding Number: RFA HD 14 024 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44) Apply for RFA HD 14 031 Funding Number: RFA HD 14 031 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01) Apply for PAR 13 389 Funding Number: PAR 13 389 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (STTR) (R41/R42) Apply for RFA HD 14 032 Funding Number: RFA HD 14 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Centers for Collaborative Research in Fragile X (U54) Apply for RFA HD 14 033 Funding Number: RFA HD 14 033 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Juvenile Protective Factors and Their Effects on Aging (R03) Apply for PAR 14 022 Funding Number: PAR 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| U.S South Africa Program for Collaborative Biomedical Research (U01) Apply for RFA AI 14 018 Funding Number: RFA AI 14 018 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $225,000 |
| Data Sharing for Demographic Research Infrastructure Program (U24) Apply for RFA HD 14 015 Funding Number: RFA HD 14 015 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Intellectual and Developmental Disabilities Research Centers 2014 (U54) Apply for RFA HD 14 012 Funding Number: RFA HD 14 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Population Dynamics Centers Research Infrastructure (P2C) Apply for RFA HD 14 016 Funding Number: RFA HD 14 016 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Data Coordinating Center for the Collaborative Pediatric Critical Care Research Network (U01) Apply for RFA HD 14 020 Funding Number: RFA HD 14 020 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 310", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.